ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effect of Combined Pharmacotherapy/Behavioral Treatment on Smoking Cessation For Methadone Maintenance Therapy Patients - 2

This study is ongoing, but not recruiting participants.

Sponsored by: National Institute on Drug Abuse (NIDA)
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00060814
  Purpose

The purpose of this pilot study is to examine the effects of combined pharmacotherapy (Zyban/NRT)/behavioral treatment on smoking cessation among methadone maintenance therapy patients.


Condition Intervention Phase
Tobacco Use Disorder
Behavioral: Bupropion
Phase II

MedlinePlus related topics:   Quitting Smoking    Smoking   

Drug Information available for:   Methadone    Methadone hydrochloride    Bupropion hydrochloride    Bupropion   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Active Control
Official Title:   Pilot Study Examining the Effects of Combined Pharmacotherapy (Zyban/NRT)/Behavioral Treatment on Smoking Cessation Among MMT Patients.

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Behavioral

Estimated Enrollment:   34
Study Start Date:   September 2002

Detailed Description:

This is a one-arm, open label pilot study of MMT patients to determine whether bupropion, nicotine replacement therapy, and behavioral counseling is a feasible and potentially effective intervention for smoking cessation. The smoking behaviors of participants will be be followed for 6 months post quit-date to determine effect-size estimates for a future, large scale trial.

  Eligibility
Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Patients in long-term methadone maintenance treatment
  • Patient smokes at least 10 cigarettes per day, are stable on their use of methadone (phase 2 or higher treatment), smoked for at least 1 year, be willing to participate for 6 months, and not have used bupropion or nicotine replacement therapy for 6 months

Exclusion Criteria:

  • Patients who use prescription drug regimens that might affect methadone or bupropion metabolism
  • Patients with cardiovascular disease, asthma, COPD
  • Patients who are pregnant or breastfeeding
  • Patients with regular use of alcohol, other illicit drugs, or other types of tobacco (chewing or pipe for example)
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00060814

Locations
United States, Kansas
University of Kansas Medical Center    
      Kansas City, Kansas, United States, 66160 7420

Sponsors and Collaborators

Investigators
Principal Investigator:     Kimber Richter, Ph.D.     University of Kansas    
  More Information


Study ID Numbers:   NIDA-00450-2, K01-00450-2
First Received:   May 14, 2003
Last Updated:   November 3, 2005
ClinicalTrials.gov Identifier:   NCT00060814
Health Authority:   United States: Federal Government

Study placed in the following topic categories:
Methadone
Smoking
Mental Disorders
Tobacco Use Disorder
Bupropion
Substance-Related Disorders
Disorders of Environmental Origin

ClinicalTrials.gov processed this record on November 30, 2008




Links to all studies - primarily for crawlers